Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma

Călin Crăciun 1 , Orsolya Hankó-Bauer 1 , Zalán Benedek 1 , Sorin Sorlea 1 , Marius Florin Coroș 1 , and Rareș Georgescu 1
  • 1 Department of Surgery, University of Medicine and Pharmacy, Tîrgu Mureș, Romania


Malignant melanoma is a neoplasia that has its origin in the melanocytes, the melanin-synthesizing pigment cells present in the epidermis or sometimes in the dermis. Sentinel lymph node biopsy (SLNB) is the standard procedure used for staging patients with malignant melanoma in the majority of surgical centers in the world. With a probability of approximately 20% of finding positive lymph nodes, it spares a large number of patients of a complete lymphatic dissection. The aim of this study is to evaluate the factors that can predict the positivity of sentinel lymph nodes in malignant melanoma patients. We performed a retrospective study analyzing the histopathologic reports of patients who underwent SLNB for malignant melanoma between 2012 and 2015. There were 32 patients identified, out of which only three (9.37%) had positive SLN, so the majority of our patients were spared of regional lymphatic dissection. In our series, lymphatic invasion (p = 0.01), Breslow index >4 mm (p = 0.0064), AJCC staging (p = 0.0008), the presence of precursory lesions (p = 002), and microsatellitosis (p = 0.017) were predictive factors for the positivity of the SLN in malignant melanoma patients. Although our results are similar to those published in the literature, we consider that larger cohort studies should be performed to consolidate our results.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Longo DL, Kasper DL, Jameson JL, et al. Harrison’s Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies/United States of America; 2012. p. 723-730.

  • 2. Tejera-Vaquerizo A, Martín-Cuevas P, Gallego E, et al. Predictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis. Actas Dermosifiliogr. 2015;106:208-218.

  • 3. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;4:270-283.

  • 4. Ellis MC, Weerasinghe R, Corless CL, et al. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg. 2010;199:663-668.

  • 5. Teixeira V, Vieira R, Coutinho I, et al. Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre. Journal of Skin Cancer. 2013;2013:7.

  • 6. Kibrité A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. Am J Surg. 2016;211:89-94.

  • 7. Morton ML, Thompson JF, Cochran AC, et al. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. N Engl J Med. 2014;370:599-609.

  • 8. Gershenwald JE, Ross MI. Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. N Engl J Med. 2011;364:1738-1745.

  • 9. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am. 2007;16:403-430.

  • 10. Faries MB, Cochran AJ, Elashoff RM, et al. Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management. Br J Dermatol. 2015;172:571-573.


Journal + Issues